These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 15019595

  • 1. The health care costs of diabetic nephropathy in the United States and the United Kingdom.
    Gordois A, Scuffham P, Shearer A, Oglesby A.
    J Diabetes Complications; 2004; 18(1):18-26. PubMed ID: 15019595
    [Abstract] [Full Text] [Related]

  • 2. Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death.
    Currie CJ, Morgan CL, Dixon S, McEwan P, Marchant N, Bearne A, Sharplin P, Peters JR.
    Diabetes Res Clin Pract; 2004 Sep; 65(3):267-74. PubMed ID: 15331207
    [Abstract] [Full Text] [Related]

  • 3. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
    Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S.
    Kidney Int Suppl; 2004 Nov; (92):S115-7. PubMed ID: 15485403
    [Abstract] [Full Text] [Related]

  • 4. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
    Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM, RENAAL Investigators.
    Pharmacoeconomics; 2006 Nov; 24(6):549-58. PubMed ID: 16761903
    [Abstract] [Full Text] [Related]

  • 5. Preventable kidney failure: the cost of diabetes neglect?
    Endre ZH, Beaven D, Buttimore A.
    N Z Med J; 2006 Dec 01; 119(1246):U2338. PubMed ID: 17151712
    [Abstract] [Full Text] [Related]

  • 6. The health care costs of diabetic peripheral neuropathy in the US.
    Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA.
    Diabetes Care; 2003 Jun 01; 26(6):1790-5. PubMed ID: 12766111
    [Abstract] [Full Text] [Related]

  • 7. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.
    J Hum Hypertens; 2004 Oct 01; 18(10):733-8. PubMed ID: 15116142
    [Abstract] [Full Text] [Related]

  • 8. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA, Firth LM, Lewis EJ.
    Diabetes Care; 1996 Oct 01; 19(10):1051-61. PubMed ID: 8886549
    [Abstract] [Full Text] [Related]

  • 9. Economic costs of diabetes in the US in 2002.
    Hogan P, Dall T, Nikolov P, American Diabetes Association.
    Diabetes Care; 2003 Mar 01; 26(3):917-32. PubMed ID: 12610059
    [Abstract] [Full Text] [Related]

  • 10. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.
    O'Brien JA, Patrick AR, Caro J.
    Clin Ther; 2003 Mar 01; 25(3):1017-38. PubMed ID: 12852716
    [Abstract] [Full Text] [Related]

  • 11. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I, Canadian Hypertension Society.
    Can J Cardiol; 2004 May 01; 20(6):613-8. PubMed ID: 15152291
    [Abstract] [Full Text] [Related]

  • 12. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association.
    Diabetes Care; 2008 Mar 01; 31(3):596-615. PubMed ID: 18308683
    [Abstract] [Full Text] [Related]

  • 13. Pharmacoeconomic challenges in the management of diabetic nephropathy.
    Rodby RA.
    J Manag Care Pharm; 2004 Sep 01; 10(5 Suppl A):S6-11. PubMed ID: 15369419
    [Abstract] [Full Text] [Related]

  • 14. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S, Citarella A, Cammarota S, Menditto E, Mantovani LG.
    Clin Exp Hypertens; 2011 Sep 01; 33(3):174-8. PubMed ID: 21466388
    [Abstract] [Full Text] [Related]

  • 15. Changing trends in end-stage renal disease due to diabetes in the United kingdom.
    Hill CJ, Fogarty DG.
    J Ren Care; 2012 Feb 01; 38 Suppl 1():12-22. PubMed ID: 22348360
    [Abstract] [Full Text] [Related]

  • 16. Maintenance dialysis population dynamics: current trends and long-term implications.
    Lysaght MJ.
    J Am Soc Nephrol; 2002 Jan 01; 13 Suppl 1():S37-40. PubMed ID: 11792760
    [Abstract] [Full Text] [Related]

  • 17. Indirect cost of HIV infection in England.
    Mullins CD, Whitelaw G, Cooke JL, Beck EJ.
    Clin Ther; 2000 Nov 01; 22(11):1333-45. PubMed ID: 11117658
    [Abstract] [Full Text] [Related]

  • 18. Diabetes mellitus and renal replacement therapy in Italy: prevalence, main characteristics and complications.
    Catalano C, Postorino M, Kelly PJ, Fabrizi F, Enia G, Goodship TH, Fulcher GR, Maggiore Q.
    Nephrol Dial Transplant; 1990 Nov 01; 5(9):788-96. PubMed ID: 2129352
    [Abstract] [Full Text] [Related]

  • 19. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM.
    Diabetes Care; 2003 Mar 01; 26(3):683-7. PubMed ID: 12610022
    [Abstract] [Full Text] [Related]

  • 20. The cost of diabetes in Latin America and the Caribbean.
    Barceló A, Aedo C, Rajpathak S, Robles S.
    Bull World Health Organ; 2003 Mar 01; 81(1):19-27. PubMed ID: 12640472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.